Skip to main content


We're creating a new version of this page. See preview

  • Commentary
  • Open Access

Wharton’s jelly mesenchymal stem cells promote wound healing and tissue regeneration

Stem Cell Research & Therapy20145:62

  • Received: 17 December 2013
  • Accepted: 11 April 2014
  • Published:


Wound healing requires an orchestrated integration of complex biological and molecular events, which include inflammation, proliferation and remodeling. Wharton’s jelly mesenchymal stem cells seem to promote wound healing and tissue repair. Wharton’s jelly stem cells promote fibroblast proliferation and migration, accelerate re-epithelialization and promote overall wound repair by pcrine signaling. Wharton’s jelly is an advantageous mesenchymal stem cell source because the harvest of this type of stem cells is not painful or invasive and because, beside their effect on wound healing, they seem to have a significant impact on the treatment of keloids. Furthermore, they led to better nerve regeneration, better neuroprotection and less inflammation.


  • Wound Healing
  • Mesenchymal Stem Cell
  • Bone Marrow MSCs
  • Stem Cell Source
  • Promote Wound Healing

Wound healing requires an orchestrated integration of complex biological and molecular events, which include inflammation, proliferation and remodeling [1]. Despite the current use and availability of a wide array of wound dressings, ointments and devices [2], wound healing still remains a clinical challenge, especially in older patients, diabetic patients, heavy smokers or burned patients [1]. Such wounds, if not treated effectively, eventually end up in amputations or disfiguring scars termed hypertrophic scars and keloids, because surgical procedures such as local or free flaps go along with limited donor site availability and require a stable general health condition of the patient. There is therefore a need for new strategies to promote or at least coadjuvantly help wound healing and tissue repair.

Skin cell renewal is under the control of mesenchymal stem cells (MSCs). Skin MSCs populate the normal skin niche, remain quiescent and become active after injury, aiding in wound closure [3]. MSC pcrine signaling is suggested to be the main underlying mechanism for the enhanced wound repair effects [4]. Treatment of wounds has therefore been attempted with the application of exogenous bone marrow MSCs. Bone marrow MSCs have been reported to promote wound healing by modulating the inflammatory environment, promoting angiogenesis and vascularization, encouraging the migration of keratinocytes and inhibiting apoptosis of wound healing cells, but their isolation requires an invasive and artificial method [1].

Adipose-derived stem cells (ADSCs) are located between mature adipocytes in the adipose tissue. ADSCs are able to differentiate into a variety of different tissues such as bone, adipose tissue and cartilage both in vitro and in vivo. Preclinical and clinical studies have shown a positive effect of ADSCs on wound healing and have verified them as a suitable cell type for skin substitution [5, 6].

ADSCs can relatively easily be harvested through liposuction or during abdominoplasty, but this still requires a surgical procedure. Researchers thus focused on a more advantageous MSC source, such as umbilical cord-derived Wharton’s jelly [7]. The harvest of this type of stem cells is not painful or invasive; the cells are isolated naturally with no extra surgeries and are dissected from discarded umbilical cords after birth. Isolation of ADSCs requires enzymatic digestion using collagenase, whereas Wharton’s jelly stem cells can optimally be generated by explant culture.

Moreover, human umbilical cord Wharton’s jelly mesenchymal stem cells (WJ-MSCs) have been shown to have better clinical utility. WJ-MSCs have unique properties between embryonic and adult stem cells. These cells have low-level expression of embryonic stem cell markers and satisfy the criteria recommended by the International Society of Cytotherapy for MSCs. Stem cell quality, quantity and safety can be optimized when cultured under controlled physiolocal conditions, including appropriate oxygen and nutrition supply as well as waste elimination. These can be realized in bioreactors using dynamic culturing strategies.

WJ-MSCs represent a very efficient stem cell source with reported immunoprivileged, anticancer and antifibrotic characteristics under in vitro conditions and in animal models [7]. Due to their reported immunoprivileged properties and universal and ever-lasting availability, their allotransplantation as an off-the-shelf therapy may represent an appropriate treatment strategy in the already compromised patients who suffer recalcitrant cutaneous wounds [3].

Indeed, caprine WJ-MSCs have already been shown to promote wound repair with minimal scarring, and the results of a recent study by Arno and colleagues suggest that WJ-MSCs enhance wound healing and tissue repair [1]. WJ-MSCs promoted fibroblast proliferation and migration, accelerated the re-epithelialization rate and promoted overall wound repair by pcrine signaling. Under culture conditions, human WJ-MSCs enhanced the expression of wound-healing promoting genes, including re-epithelialization, neovascularization and fibroproliferation. Under culture conditions, significantly enhanced proliferation and migration were observed. This is an important observation because cellular dynamics and cell migration constitute an essential step during cutaneous healing. WJ-MSCs accelerated wound closure both in vitro and in an in vivo mouse wound healing model, suggesting that human WJ-MSCs may promote wound repair. Indeed, pilot clinical studies have so far indicated that MSCs in general are safe in vivo, and they currently represent the most widely used stem cells in the clinical setting [8]. Accordingly, in the particular case of WJ-MSCs, 15 diabetic patients received WJ-MSCs systemically with no documented relevant safety concerns [9].

In conclusion, Wharton’s jelly is an advantageous MSC source, because the harvest of this type of stem cells is not painful or invasive and because, in addition to their effect on wound healing, they seem to have a significant impact on the treatment of keloids. Furthermore, the cells led to better nerve regeneration [10], better neuroprotection and less inflammation. Also, the isolation of WJ-MSCs seems to be more efficient and the cells have a higher capacity of proliferation and are less senescent than ADSCs. Even if proper studies comparing the wound-healing abilities of different MSC sources are still lacking in the literature, at least a new preclinical and clinical research field investigating the potential of WJ-MSCs in wounds and wound healing has arrived.



Adipose-derived stem cell


Mesenchymal stem cell


Wharton’s jelly mesenchymal stem cell.


Authors’ Affiliations

Division of Plastic, Aesthetic and Reconstructive Surgery, Research Unit for Tissue Regeneratjion, Repair and Reconstruction, Department of Surgery, Medical University of Graz, Auenbruggerplatz 29, Graz, A-8036, Austria
Division of Plastic and Reconstructive Surgery, Department of Surgery, Medical University of Vienna, Waehringer Guertel 18-20, A-1090 Vienna, Austria
Department of Biotechnology, University of Natural Resources and Life Sciences, Muthgasse 18, Vienna, A-1190, Austria


  1. Arno AI, Amini-Nik S, Blit PH, Al-Shehab M, Belo C, Herer E, Tien CT, Jeschke MG: Human Wharton’s jelly mesenchymal stem cells promote skin wound healing through pcrine signaling. Stem Cell Res Ther. 2014, 5: 28-10.1186/scrt417.PubMed CentralView ArticlePubMedGoogle Scholar
  2. Selig HF, Lumenta DB, Giretzlehner M, Jeschke MG, Upton D, Kamolz LP: The properties of an ‘ideal’ burn wound dressing – what do we need in daily clinical practice? Results of a worldwide online survey among burn care specialists. Burns. 2012, 38: 960-966. 10.1016/j.burns.2012.04.007.View ArticlePubMedGoogle Scholar
  3. Arno A, Smith AH, Blit BH, Al-Shehab M, Gauglitz G, Jeschke MG: Stem cell therapy: a new treatment for burns?. Pharmaceuticals. 2011, 4: 1355-1380. 10.3390/ph4101355.PubMed CentralView ArticleGoogle Scholar
  4. Li H, Fu X: Mechanisms of action of mesenchymal stem cells in cutaneous wound repair and regneration. Cell Tissue Res. 2012, 348: 371-377. 10.1007/s00441-012-1393-9.View ArticlePubMedGoogle Scholar
  5. Hanson SE, Bentz ML, Hematti P: Mesenchymal stem cell therapy for nonhealing cutaneous wounds. Plast Reconstr Surg. 2010, 125: 510-516. 10.1097/PRS.0b013e3181c722bb.PubMed CentralView ArticlePubMedGoogle Scholar
  6. van den Broek LJ, Kroeze KL, Waaijman T, Breetveld M, Sampat-Sardjoepersad SC, Niessen FB, Middelkoop E, Scheper RJ, Gibbs S: Differential response of human adipose tissue-derived mesenchymal stem cells, dermal fibroblasts, and keratinocytes to burn wound exudates: potential role of skin-specific chemokine CCL27. Tissue Eng Part A. 2014, 20: 197-209. 10.1089/ten.tea.2013.0123.PubMed CentralView ArticlePubMedGoogle Scholar
  7. Bongso A, Fong CY: The therapeutic potential, challenges and future clinical directions of stem cells from the Wharton’s jelly of the human umbilical cord. Stem Cell Rev. 2013, 9: 226-240. 10.1007/s12015-012-9418-z.View ArticlePubMedGoogle Scholar
  8. Haas R, Kasper C, Bohm S, Jacobs R: Different populations and sources of human mesenchymal stem cells (MSC): a comparison of adult and neonatal tissue-derived MSC. Cell Commun Signal. 2011, 9: 12-10.1186/1478-811X-9-12.View ArticleGoogle Scholar
  9. Hu JYX, Wang Z, Wang L, Gao H, Chen Y, Zhao W, Jia Z, Yan S, Wang Y: Long term effects of the implantation of Wharton’s jelly-derived mesenchymal stem cells from the umbilical cord for newly-onset type 1 diabetes mellitus. Endocr J. 2013, 60: 347-357. 10.1507/endocrj.EJ12-0343.View ArticlePubMedGoogle Scholar
  10. Gärtner A, Pereira T, Alves MG, Armada-da-Silva PA, Amorim I, Gomes R, Ribeiro J, França ML, Lopes C, Carvalho RA, Socorro S, Oliveira PF, Porto B, Sousa R, Bombaci A, Ronchi G, Fregnan F, Varejão AS, Luís AL, Geuna S, Maurício AC: Use of poly(DL-lactide-ε-caprolactone) membranes and mesenchymal stem cells from the Wharton’s jelly of the umbilical cord for promoting nerve regeneration in axonotmesis: in vitro and in vivo analysis. Differentiation. 2012, 84: 355-365. 10.1016/j.diff.2012.10.001.View ArticlePubMedGoogle Scholar


© Kamolz et al.; licensee BioMed Central Ltd. 2014

This article is published under license to BioMed Central Ltd. The licensee has exclusive rights to distribute this article, in any medium, for 12 months following its publication. After this time, the article is available under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.